Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 20686621)

1.

Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model.

Vempati P, Mac Gabhann F, Popel AS.

PLoS One. 2010 Jul 29;5(7):e11860. doi: 10.1371/journal.pone.0011860.

2.

Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis.

Vempati P, Popel AS, Mac Gabhann F.

BMC Syst Biol. 2011 May 2;5:59. doi: 10.1186/1752-0509-5-59.

3.

Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Vempati P, Popel AS, Mac Gabhann F.

Cytokine Growth Factor Rev. 2014 Feb;25(1):1-19. doi: 10.1016/j.cytogfr.2013.11.002. Epub 2013 Nov 27. Review.

5.

The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.

Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N.

J Biol Chem. 1996 Mar 29;271(13):7788-95.

8.

VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis.

Hawinkels LJ, Zuidwijk K, Verspaget HW, de Jonge-Muller ES, van Duijn W, Ferreira V, Fontijn RD, David G, Hommes DW, Lamers CB, Sier CF.

Eur J Cancer. 2008 Sep;44(13):1904-13. doi: 10.1016/j.ejca.2008.06.031. Epub 2008 Aug 6.

PMID:
18691882
9.

Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165.

Gengrinovitch S, Berman B, David G, Witte L, Neufeld G, Ron D.

J Biol Chem. 1999 Apr 16;274(16):10816-22.

10.

Complex receptor-ligand dynamics control the response of the VEGF system to protease injury.

Forsten-Williams K, Kurtagic E, Nugent MA.

BMC Syst Biol. 2011 Oct 21;5:170. doi: 10.1186/1752-0509-5-170.

11.
12.

VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix.

Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G.

J Biol Chem. 1997 Mar 14;272(11):7151-8.

13.
14.

Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors.

Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML.

J Cell Biol. 2005 May 23;169(4):681-91.

15.

Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165.

Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y.

J Biol Chem. 2002 Sep 27;277(39):36288-95. Epub 2002 Jul 11.

16.

Generation of a chimeric plasmin-resistant VEGF165/VEGF183 (132-158) protein and its comparative activity.

Huiyong Z, Yong L, Yunxiao S, Wuling Z, Jingjing L, Taiming L.

Protein Pept Lett. 2013 Aug;20(8):947-54.

PMID:
23469806
17.

Regulation of vascular endothelial growth factor binding and activity by extracellular pH.

Goerges AL, Nugent MA.

J Biol Chem. 2003 May 23;278(21):19518-25. Epub 2003 Mar 11.

18.

Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms.

Gengrinovitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, Levi BZ, Neufeld G.

J Biol Chem. 1995 Jun 23;270(25):15059-65.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk